| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2969619 | The Journal of Heart and Lung Transplantation | 2016 | 20 Pages |
Abstract
New allosensitization takes place in > 20% of patents supported with CF LVADs. Among patients who undergo transplant, this results in a higher risk of ACR and AMR, but survival remains favorable, likely due to the efficacy of current management after transplant. However, mortality in sensitized patients who do not reach transplant remains high, and new approaches are necessary to meet the needs of this group of patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Byung-Soo MD, Stavros MD, PhD, Abdallah G. MD, Denise MS, Gregory J. MPH, Carrie A. MD, Julio C. MD, MS, Elizabeth H. MD, Edward M. MD, Rami MD, Monica P. MD, PhD, Jose MD, Bruce B. MD, Stephen H. MD, MS, Omar MD, Dylan V. MD, David D. MD, James C. MD,